Loading page
Loading page
Loading substance route
DOM is highly dose-sensitive and notably potent relative to other phenethylamines. Tolerance develops rapidly after administration, requiring approximately 7 days to return to baseline in the absence of repeated use.
Effects vary widely by individual, dose, and context.
The physical effects of DOM can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of DOM are described by many as a combination of extreme mental stimulation and a powerful enhancement of a person's current mental state.
DOM presents a full and complete array of possible visual enhancements.
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of 4-AcO-DMT or ayahuasca than that of LSD, 2C-B or 2C-I. It can be comprehensively described through its variations as intricate in style, equally algorithmic and abstract in form, equally synthetic and organic in style, structured in organization, brightly lit in lighting, multicoloured in scheme, glossy in shading, sharp in edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in depth and consistent in intensity. Higher dosages are significantly more likely to result in states of Level 8A visual geometry over Level 8B.
DOM produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. This holds particularly true in comparison to other substances within the phenethylamine family.
The auditory effects of DOM are common in their occurrence and exhibit a full range of effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
DOM is not habit-forming and the desire to use it typically decreases with use. It exhibits a self-regulating quality that discourages compulsive redosing or frequent administration.
DOM is not physically addictive and does not produce physical dependence or withdrawal symptoms.
Human deaths have not been documented even at doses exceeding 20-30 mg, though such doses cannot be considered safe. The exact toxic dose in humans remains unknown due to limited formal research.
| Species | Route | Value |
|---|---|---|
| mouse | unspecified | 100 mg/kg |
DOM produces pronounced cardiovascular stimulation including large increases in heart rate and blood pressure during intoxication; these effects are described as more worrisome than those seen with classic psychedelics like LSD, and severe vasoconstriction may develop at high doses.
DOM can induce psychotic states particularly at high doses, manifesting as an amphetamine psychosis-like condition with bizarre, delusional, and sometimes violent behavior. Frequent use carries risk of persistent reality distortion and may trigger latent psychoses in predisposed individuals. The exceptionally long duration increases psychological burden and likelihood of adverse psychological reactions.
Seizures are a potential risk primarily at high or overdose-level doses. Those predisposed to seizures may be at elevated risk, particularly when DOM is combined with other substances that lower seizure threshold.
DOM was first synthesized by Alexander Shulgin in 1963. The initial step of the synthesis was performed by his then fifteen-year-old son Theodore "Ted" Shulgin at Dow Chemical Company on June 22, 1963, during a brief period when the younger Shulgin had developed an interest in chemistry. Alexander…
Prohibited under a blanket ban covering all substituted phenethylamines, which includes the entire DOx family of compounds.
Listed under HOOFDSTUK II of Belgian controlled substances legislation. Possession, distribution, and production are prohibited.
Controlled substance under the Controlled Drugs and Substances Act. Possession, trafficking, and production are criminal offenses.
Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since April 15, 1971. Manufacturing, possession, import, export, buying, selling, procuring, or dispensing without a license is illegal.
Classified as a Schedule I controlled substance under Latvian drug control legislation.
Classified as a Schedule I substance in the Russian Federation. Buying, selling, or possessing without a license is illegal.
Controlled under the Misuse of Drugs Act 1971. Buying, selling, or possessing without a license is prohibited.
Controlled under the SMG (Suchtmittelgesetz Österreich). Possession, production, and sale are prohibited.
Listed on Portaria SVS/MS nº 344 under the name 'STP'. Possession, production, and sale are prohibited.
Classified as a Schedule I controlled substance under national drug legislation.
Listed in Tabella I of the 'Tabelle delle sostanze stupefacenti e psicotrope'. Possession, purchase, and sale are illegal.
Controlled as a Class A substance, the most restrictive classification under New Zealand's Misuse of Drugs Act.
Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation.
Controlled under the Controlled Substances Act. Manufacturing, buying, possessing, or distributing without a DEA license is illegal.
14 sources cited
